3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Sarcoma, Kaposi
2
Sarcoma
2
Ovarian Neoplasms
2
Multiple Myeloma
2
Melanoma
2
Hemangioma, Capillary
2
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Ulcer
1
Tuberous Sclerosis
1
Triple Negative Breast Neoplasms
1
Smoldering Multiple Myeloma
1
Skin Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Lymphatic Metastasis
1
Liver Neoplasms
1
Fallopian Tube Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
3
Paclitaxel
3
Doxorubicin
3
durvalumab
2
Standard of Care
2
Nivolumab
2
Ipilimumab
2
Ifosfamide
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
talazoparib
1
spartalizumab
1
sintilimab
1
selinexor
1
sarilumab
1
regorafenib
1
pexidartinib
1
pertuzumab
1
peginterferon alfa-2a
1
pazopanib
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
eribulin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Hemangiosarcoma
×
Propranolol
×
1 year
×
Clear all
No trials found.